The obesity drug pipeline in 2026 is the most crowded it has ever been, and the coverage of it is frequently misleading. Drugs still in phase 3 trials get written about as though they are available. They are not. Here is what is actually approved, what is under review, and what remains investigational — with the distinction stated clearly, because it determines whether you can get any of it.
Approved and available now
- Wegovy (semaglutide injection) — the established weekly injectable for weight management, plus Wegovy HD at 7.2 mg approved March 2026.
- Wegovy pill (oral semaglutide 25 mg) — launched January 5, 2026. Requires empty-stomach dosing.
- Zepbound (tirzepatide) — the dual GIP/GLP-1 agonist, and the most effective agent in trial data for weight reduction.
- Foundayo (orforglipron) — approved April 1, 2026. The first GLP-1 pill with no food or water restrictions.
- Saxenda (liraglutide) — the older daily injectable, largely superseded but still available.
Under FDA review
CagriSema combines semaglutide with cagrilintide, an amylin analogue, in a once-weekly injection. It is under FDA review with approval expected later in 2026.
The mechanism is worth understanding because it is genuinely different. Amylin is a hormone co-secreted with insulin that slows gastric emptying and promotes satiety through a separate pathway from GLP-1. Combining the two attacks appetite from two directions rather than pushing harder on one. If approved, it would be the first amylin-based combination available.
Investigational — not approved, not available
These eight late-stage compounds are frequently written about as though they are around the corner. As of mid-2026 none is FDA-approved and none can be legally prescribed for weight management in the US.
- Retatrutide — Eli Lilly's triple agonist (GLP-1, GIP, and glucagon). Still phase 3 as of July 2026 with no announced NDA submission. The most hyped compound in the pipeline and the furthest from your pharmacy.
- MariTide — Amgen's long-acting candidate, notable for a dosing interval measured in months rather than weeks.
- Survodutide — a GLP-1/glucagon dual agonist. Showed 16.6% weight loss at 76 weeks in the SYNCHRONIZE-1 trial.
- Mazdutide — a GLP-1/glucagon dual agonist developed primarily for the Chinese market.
- Ecnoglutide — a long-acting GLP-1 analogue in late-stage development.
- Pemvidutide — a GLP-1/glucagon dual agonist with a body-composition emphasis.
- Petrelintide — an amylin analogue being developed as a standalone rather than a combination.
- CagriSema — included here in some trackers, though it has progressed to FDA review.
Why "investigational" matters to you specifically
An investigational compound cannot be legally prescribed for weight management. It also cannot be legally compounded — compounding pharmacies work from approved active pharmaceutical ingredients, and an unapproved investigational drug does not qualify.
This matters because retatrutide in particular is widely sold through grey-market "research peptide" channels. Those products are not manufactured under pharmaceutical quality controls, are not tested for sterility or potency, and are explicitly labeled not for human use. People inject them anyway.
If a provider offers you retatrutide, that is a signal to leave. There is no legitimate route to it outside a clinical trial.
Should you wait for something better?
Generally, no. The approved options in 2026 are genuinely effective — tirzepatide produced roughly 20.9% average weight loss at the highest dose in SURMOUNT-1, which is close to bariatric surgery territory. Waiting two or three years for a compound that may produce a few additional percentage points means two or three more years at your current weight.
Obesity-related conditions — cardiovascular risk, sleep apnea, fatty liver, joint degeneration — progress during the wait. The best treatment is the effective one you can start now.
Bottom line
Five GLP-1 products are approved and available, one is under review, and eight remain investigational. The gap between "promising phase 3 data" and "available at your pharmacy" is typically several years and is not guaranteed to close at all.
Start with what exists. See our semaglutide vs tirzepatide comparison for choosing between the two most effective approved options.